Neuberger Berman Group’s Stemline Therapeutics, Inc. STML Stock Holding History

Neuberger Berman Group’s Portfolio STML Stock Details STML Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q4	–	Sell	-56,228	Closed	-$585K	–	1624
2019 Q3	$585K	Sell	56,228 -39,772	-41%	-$520K	﹤0.01%	1248
2019 Q2	$1.47M	Buy	96,000 +36,000	+60%	+$521K	﹤0.01%	1093
2019 Q1	$771K	Buy	+60,000	New	+$678K	﹤0.01%	1170
2018 Q4	–	Sell	-60,500	Closed	-$1M	–	1696
2018 Q3	$1M	Buy	60,500 +8,000	+15%	+$128K	﹤0.01%	1192
2018 Q2	$843K	Buy	+52,500	New	+$937K	﹤0.01%	1283
2013 Q3	–	Sell	-227,759	Closed	-$5.43M	–	1690
2013 Q2	$5.43M	Buy	+227,759	New	+$3.63M	0.01%	872

Other funds holding STML

EAM

Eventide Asset Management Boston, Massachusetts $6.05B AUM 76.64% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

RCMNY

Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return

Manulife (Manufacturers Life Insurance) Canada, Ontario, Canada $116B AUM 26.37% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

FCM

Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Polar Capital London, United Kingdom $13.5B AUM 55.9% 1-Year Est. Return

AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return

Neuberger Berman Group's STML Position: Q4 2019 in Review

Neuberger Berman Group sold out of Stemline Therapeutics, Inc. (STML) in Q4 2019, closing a stake of 56,228 shares — an estimated $585K sold.

Neuberger Berman Group first reported a position in STML in Q2 2013 and held it in 6 quarters. The position peaked at $5.43M in Q2 2013. 99 funds tracked by Wall St. Rank hold STML as of Q4 2019.

Neuberger Berman Group reported no remaining Stemline Therapeutics, Inc. position as of Q4 2019 after selling out during the quarter.
Neuberger Berman Group sold 56,228 Stemline Therapeutics, Inc. shares in Q4 2019, an estimated $585K.
Neuberger Berman Group first reported a position in Stemline Therapeutics, Inc. in Q2 2013 and held it in 6 quarters.
Neuberger Berman Group's Stemline Therapeutics, Inc. position peaked at $5.43M in Q2 2013.
99 funds tracked by Wall St. Rank held Stemline Therapeutics, Inc. as of Q4 2019.

Based on Neuberger Berman Group's 13F filing for Q4 2019, filed 12 Feb 2020.